Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal MedScientiae
Nahak, Petronela Bhoko
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Perbandingan Efektivitas Injeksi Agen-Agen Anti-Vegf pada Pengobatan Age-Related Macular Degeneration Nahak, Petronela Bhoko; Arsita, Elli; Wastitiamurti, Ritsia Anindita
Jurnal MedScientiae Vol. 3 No. 1 (2024): April
Publisher : Universitas Kristen Krida Wacana

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36452/JMedScientiae.v3i1.3143

Abstract

Age-related macular degeneration (AMD) is one of the leading causes of blindness in people >60 years of age in developed countries. The pathogenesis of neovascular AMD involves increased choroidal vascular permeability, leading to hypoxia and the production of pro-inflammatory and pro-angiogenic factors, particularly vascular endothelial growth factor (VEGF). Treatment of neovascular AMD involves anti-VEGF therapy, which inhibits abnormal blood vessel growth. Numerous studies have demonstrated the effectivity and side effects of each Anti-VEGF agent. Based on this background, the author is interested in conducting a literature review that summarizes the effectivity and side effects of each Anti-VEGF agent. The method used was Literature Review. Journals were collected using GoogleScholar or Google Scholar, PubMed and Proquest within the last 10 years. A total of 10 journals that met the inclusion-exclusion criteria were reviewed and tested for eligibility with the Ottawa score. The results of this literature review showed that anti-VEGF agents including bevacizumab, ranibizumab, aflibercept, pegaptanib sodium, brolucizumab and abicipar pegol have been shown to be equally effective in improving vision and maintaining stable vision in neovascular AMD patients. However, these anti-VEGF treatments can also cause side effects such as intraocular inflammation, increased intraocular pressure and vascular problems.
Co-Authors Elli Arsita Wastitiamurti, Ritsia Anindita